VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day VRTX SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
5.7%
8/1/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
MISS
-2.2%
5/6/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
1.9%
2/5/2024
04:06 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-2.7%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX
SPY
QQQ
SPX
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/24
07:41 pm
vrtx
Neutral
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know [Yahoo! Finance]
12/23
04:05 pm
vrtx
Low
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
12/23
03:19 pm
vrtx
Low
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
12/23
10:31 am
vrtx
Low
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
12/23
10:31 am
vrtx
Low
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
12/23
09:08 am
vrtx
Low
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.
12/23
07:45 am
vrtx
Low
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
12/20
03:46 pm
vrtx
Low
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
12/20
03:35 pm
vrtx
Neutral
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
11/4/2024
04:01 pm
vrtx
5.7%
BEAT
8/1/2024
04:01 pm
vrtx
-2.2%
MISS
5/6/2024
04:01 pm
vrtx
1.9%
BEAT
2/5/2024
04:06 pm
vrtx
-2.7%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/23
10:11 am
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
2.5%
12/23
10:11 am
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
2.5%
12/23
08:57 am
Maintains
Overweight
Overweight
JP Morgan
Low
2.6%
12/20
01:14 pm
Maintains
Equal-Weight
Equal-Weight
Barclays
Low
-0.5%
12/20
01:14 pm
Maintains
Equal-Weight
Equal-Weight
Barclays
Low
-0.5%
12/20
11:35 am
Maintains
Outperform
Outperform
BMO Capital
Low
1.2%
12/20
11:35 am
Maintains
Outperform
Outperform
BMO Capital
Low
1.2%
12/20
08:19 am
Reiterates
Hold
Hold
Needham & Company LLC
Low
0.3%
12/20
07:55 am
Reiterates
Hold
Hold
Needham
Low
0.3%
12/20
03:52 pm
vrtx
Low
Form 8-K VERTEX PHARMACEUTICALS For: Dec 20
11/19
04:09 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Nov 15 Filed by: ALTSHULER DAVID
11/15
10:31 am
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: ALTSHULER DAVID
11/13
04:15 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Nov 11 Filed by: WAGNER CHARLES F JR
11/12
04:09 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Nov 08 Filed by: Kewalramani Reshma
11/12
09:44 am
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
11/8
02:59 pm
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: Kewalramani Reshma
11/5
04:13 pm
vrtx
Low
Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30
11/4
04:03 pm
vrtx
Medium
Form 8-K VERTEX PHARMACEUTICALS For: Nov 04
Show more
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%